Abbott Laboratories and Battelle Pulmonary Therapeutics Announce License Agreement
ABBOTT PARK, Ill., June 29 /PRNewswire/ -- Abbott Laboratories, Ross Products Division and Battelle Pulmonary
Therapeutics, Inc. (BPT), announced today an agreement under which BPT will license to Abbott new products and drug
delivery technology to develop therapies for a variety of respiratory diseases.
``Battelle and Abbott have had a long, successful history in the development of proprietary devices for the delivery of nutritional products,'' said Joy Amundson, senior vice president, Ross Products Division. ``We look forward to expanding this relationship into the area of pharmaceutical products for respiratory diseases.''
``We are very encouraged by this business relationship and the laboratory work we have done so far on new pulmonary
therapies,'' said Dennis Cearlock, president and chief executive officer, Battelle Pulmonary Therapeutics, a subsidiary of Battelle Memorial Institute. ``Abbott has formulation and manufacturing expertise in proprietary respiratory disease compounds and BPT has expertise in drug delivery device technology. The collaboration between the two companies' research groups will provide a critical mass to develop new therapies together and move forward with clinical development.''
Looking good here and nice to see it over 43...whew.
chris |
